NeuroPace (NeuroPace) Debt-to-Revenue : 1.01 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroPace Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

NeuroPace's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.68 Mil. NeuroPace's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $71.40 Mil. NeuroPace's annualized Revenue for the quarter that ended in Mar. 2024 was $72.50 Mil. NeuroPace's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 1.01.

NeuroPace Debt-to-Revenue Historical Data

The historical data trend for NeuroPace's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace Debt-to-Revenue Chart

NeuroPace Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

1.70

1.29

1.10

1.53

1.11

NeuroPace Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial													1.22	1.08	1.09	1.01	1.01

Competitive Comparison of NeuroPace's Debt-to-Revenue

For the Medical Devices subindustry, NeuroPace's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroPace's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NeuroPace's Debt-to-Revenue falls into.

NeuroPace Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NeuroPace's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.627	+	70.768)	/	65.421
	=	1.11

NeuroPace's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.683	+	71.402)	/	72.496
	=	1.01

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

NeuroPace Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeuroPace's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroPace (NeuroPace) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

455 N. Bernardo Avenue, Mountain View, CA, USA, 94043

Website

https://www.neuropace.com

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Executives

Martha Morrell	officer: Chief Medical officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd.	10 percent owner	CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker	director, officer: Chief Executive Officer	ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger	director	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley	officer: General Counsel and Secretary	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade	director	6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield	director	C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer	director	9701 JERONIMO, IRVINE CA 92618
Evan Norton	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob	director	2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet	director, officer: Chief Executive Officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043